Albert David Limited has informed the Exchange about General Updates regarding re-appointment of Internal Auditors for FY 2025-26.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited announced audited financial results for Q4 and FY ended March 31, 2025, with the statutory auditor (L. B. Jha & Co.) issuing an unmodified opinion. Revenue from operations fell to Rs. 34,576.80 lakhs from Rs. 36,246.17 lakhs in FY24, a decline of about 4.6%. Profit for the year dropped sharply to Rs. 1,720.08 lakhs from Rs. 7,542.01 lakhs in FY24, while Q4 FY25 slipped into a loss of Rs. 1,032.79 lakhs versus a profit of Rs. 1,291.26 lakhs in the year-ago quarter. The Board recommended a final dividend of Rs. 5 per share (50% on face value of Rs. 10) for FY25, with record date set for July 25, 2025. PwC was reappointed as Internal Auditor for FY26, MKB & Associates appointed as Secretarial Auditor for 5 years (FY26–FY30), and S. Gupta & Co. reappointed as Cost Auditor for FY26.
Despite an unmodified audit opinion and a healthy dividend, shareholders should note the sharp ~77% fall in annual profit, a Q4 loss, and a swing to negative operating cash flow of Rs. 2,843.58 lakhs (vs. Rs. 4,550.22 lakhs inflow last year), which signals margin and working capital pressure that could weigh on near-term sentiment.